What is the half-life of Semax?

Semax has a half-life of ~3-5 minutes (active metabolites persist longer), which is why it's typically administered 1-3 times daily for optimal therapeutic effect.

How do I reconstitute Semax?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 3

Semax

Also known as: SEMAX, Heptapeptide Semax, MEHFPGP

Overview

Key Facts

Primary Goal: A synthetic heptapeptide derived from the ACTH(4-10) fragment with a Pro-Gly-Pro (PGP) tripeptide extension at the C-terminus that confers enzymatic stability

A synthetic heptapeptide derived from the ACTH(4-10) fragment with a Pro-Gly-Pro (PGP) tripeptide extension at the C-terminus that confers enzymatic stability. Originally developed in Russia and approved there as a prescription nootropic and neuroprotective agent, Semax enhances BDNF expression and modulates monoamine neurotransmitter systems. Half-Life ~3-5 minutes (active metabolites persist longer) Typical Dose 200–600 mcg Frequency 1-3 times daily Cycle Length 10-30 days (per Russian clinical protocols)

Dosing Information

Half-Life

~3-5 minutes (active metabolites persist longer)

Typical Dose

200–600 mcg

Frequency

1-3 times daily

Cycle Length

10-30 days (per Russian clinical protocols)

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 3

Semax has been approved in Russia and several CIS countries since 1994 for conditions including stroke recovery, cognitive impairment, and optic nerve atrophy. Russian clinical trials demonstrated improved cognitive scores in mail-stroke patients and enhanced memory in healthy volunteers. Research shows robust BDNF upregulation (2-4 fold increases in hippocampal tissue) and significant neuroprotection in ischemia models. It is one of the most well-studied nootropic peptides globally, though it lacks Western regulatory trials.